A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

240

Participants

Timeline

Start Date

April 22, 2020

Primary Completion Date

August 30, 2022

Study Completion Date

March 17, 2026

Conditions
Advanced ER-Positive HER2-Negative Breast Cancer
Interventions
DRUG

AZD9833

Dosage formulation: AZD9833 tablets will be administered orally.

DRUG

Fulvestrant

Dosage formulation: Fulvestrant will be administered via intramuscular (IM) injection.

Trial Locations (91)

1122

Research Site, Budapest

2930

Research Site, Brasschaat

3000

Research Site, Leuven

4032

Research Site, Debrecen

4400

Research Site, Nyíregyháza

5000

Research Site, Namur

5100

Research Site, Umbria

6000

Research Site, Charleroi

Research Site, Batumi

Research Site, Kecskemét

6725

Research Site, Szeged

6800

Research Site, Libramont-Chevigny

7100

Research Site, Haine-Saint-Paul

7400

Research Site, Kaposvár

7624

Research Site, Pécs

9000

Research Site, Ghent

10408

Research Site, Goyang-si

10707

Research Site, Berlin

18009

Research Site, Cherkasy

20121

Research Site, Milan

20141

Research Site, Milan

20900

Research Site, Monza

22100

Research Site, Nahariya

28033

Research Site, Madrid

28050

Research Site, Madrid

33705

Research Site, St. Petersburg

33901

Research Site, Fort Myers

35205

Research Site, Birmingham

37203

Research Site, Nashville

37404

Research Site, Chattanooga

40138

Research Site, Bologna

40225

Research Site, Düsseldorf

41013

Research Site, Seville

44710

Research Site, Canton

45136

Research Site, Essen

47014

Research Site, Meldola

49102

Research Site, Dnipro

50009

Research Site, Zaragoza

54519

Research Site, Vandœuvre-lès-Nancy

54521

Research Site, Eagle River

58013

Research Site, Chernivtsі

68506

Research Site, Lincoln

75005

Research Site, Paris

80131

Research Site, Napoli

88000

Research Site, Uzhhorod

88100

Research Site, Catanzaro

90806

Research Site, Long Beach

91031

Research Site, Jerusalem

98158

Research Site, Messina

115478

Research Site, Moscow

123056

Research Site, Moscow

197082

Research Site, Saint Petersburg

197758

Research Site, Saint Petersburg

305035

Research Site, Kursk

350040

Research Site, Krasnodar

357502

Research Site, Pyatigorsk

390011

Research Site, Ryazan

400138

Research Site, Volgograd

420029

Research Site, Kazan'

4941492

Research Site, Petah Tikva

9112001

Research Site, Jerusalem

J4V 2H1

Research Site, Greenfield Park

H1T 2M4

Research Site, Montreal

H3T 1E2

Research Site, Montreal

'0112

Research Site, Tbilisi

'0159

Research Site, Tbilisi

'0186

Research Site, Tbilisi

0159

Research Site, Tbilisi

0186

Research Site, Tbilisi

00128

Research Site, Roma

85-796

Research Site, Bydgoszcz

93-513

Research Site, Lodz

64-920

Research Site, Piła

35-021

Research Site, Rzeszów

60-185

Research Site, Skorzewo

02-781

Research Site, Warsaw

2805-267

Research Site, Almada

1400-038

Research Site, Lisbon

1449-005

Research Site, Lisbon

1649-035

Research Site, Lisbon

1998-018

Research Site, Lisbon

2674-514

Research Site, Loures

4099-001

Research Site, Porto

405-760

Research Site, Incheon

08035

Research Site, Barcelona

08190

Research Site, Barcelona

03039

Research Site, Kyiv

02094

Research Site, M. Kyiv

08173

Research Site, S. Khodosivka

DE22 3NE

Research Site, Derby

LE1 5WW

Research Site, Leicester

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY